BeyondSpring (BYSI) Receivables - Other (2018 - 2019)

BeyondSpring (BYSI) posted Receivables - Other of $381000.0 for Q1 2019, down 20.79% sequentially from $481000.0 in Q4 2018.

BeyondSpring (BYSI) Receivables - Other (2018 - 2019) Analysis & Trends

BeyondSpring has reported Receivables - Other for 2 years, with the latest figure at $381000.0 in Q1 2019.

Quarterly Receivables - Other changed N/A year-over-year to $381000.0 in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $381000.0 (changed N/A YoY) and the FY2018 annual result came in at $481000.0, changed N/A from the prior year.
Receivables - Other declined to $381000.0 in Q1 2019 per BYSI's latest filing, from $481000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $481000.0 in Q4 2018 and troughed at $381000.0 in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.65 Bn	131.79 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.08 Bn	78.09 Bn	3.93 Bn
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn
4	Moderna	63.25 Bn	58.11 Bn	52.00 Mn
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.26 Bn	27.95 Bn	992.69 Mn
7	BioNTech SE	28.96 Bn	10.57 Bn	668.28 Mn
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn
9	Royalty Pharma	27.19 Bn	26.35 Bn	-
10	BeyondSpring	29.20 Mn	29.20 Mn	-

Download Data